Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma

  • Antibodies (Basel). 2022 Mar 24;11(2):22. doi: 10.3390/antib11020022.
Waqqas Tai  1 ,  Ahsan Wahab  2 ,  Diana Franco  3 ,  Zunairah Shah  4 ,  Aqsa Ashraf  5 ,  Qurrat-Ul-Ain Abid  6 ,  Yaqub Nadeem Mohammed  7 ,  Darshan Lal  8 ,  Faiz Anwer  9
Affiliations
  • 1. Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY 11201, USA.
  • 2. Department of Internal Medicine, Prattville Baptist Hospital, Prattville, AL 36066, USA.
  • 3. Department of Internal Medicine, Loyola MacNeal Hospital, Berwyn, IL 60402, USA.
  • 4. Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL 60640, USA.
  • 5. Department of Internal Medicine, Northwell Health, Mather Hospital, Port Jefferson, NY 11777, USA.
  • 6. Department of Internal Medicine, AMITA Health Saint Joseph Hospital, Chicago, IL 60657, USA.
  • 7. Department of Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, MI 48341, USA.
  • 8. Department of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV 89102, USA.
  • 9. Taussig Cancer Center, Myeloma Program, Cleveland Clinic, Cleveland, OH 44106, USA.
PMID: 35466275 DOI: 10.3390/antib11020022
Abstract

Multiple myeloma (MM) is characterized by malignant proliferation of malignant plasma cells; it is the second most common hematological malignancy associated with significant morbidity. Genetic intricacy, instability, and diverse clinical presentations remain a barrier to cure. The treatment of MM is modernized with the introduction of newer therapeutics agents, i.e., target-specific monoclonal antibodies. The currently available literature lacks the benefits of newer targeted therapy being developed with an aim to reduce side effects and increase effectiveness, compared to conventional chemotherapy regimens. This article aims to review literature about the current available monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies for the treatment of MM.

Keywords
antibody; antibody drug conjugate; bispecific antibody; immunotherapy; multiple myeloma; targeted therapy.
Products